Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after AUTO CAR T-cell therapy
NL-OMON46028Phase 2Withdrawn
- Sponsor
- Autolus Therapeutics plc
- Start
- Aug 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in plasma cell neoplasm, B-cell non-Hodgkin lymphoma (B-NHL), non-Hodgkin lymphoma, T-cell and 1 more, sponsored by Autolus Therapeutics plc. Primary endpoints: Incidence of serious adverse events related to AUTO CAR T cell therapy, New malignancies and 1 more. Planned start Aug 2018; status: withdrawn.
02
Conditions
plasma cell neoplasmB-cell non-Hodgkin lymphoma (B-NHL)non-Hodgkin lymphoma, T-cellleukemia
Beyond the preview
Go deeper on NL-OMON46028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46028.